TURALIO Access Central is now TURALIO4U. Our commitment to helping patients receive their prescribed TURALIO treatment remains the same. Learn More.

×

Please see full Prescribing Information, Including Boxed Warning and Medication Guide

This information is intended for US healthcare professionals and/or healthcare professionals involved in healthcare reimbursement only.

For US Healthcare Professionals For Patients
support
Need support?
Connect live with Daiichi Sankyo AccessCentral4U

1-866-4-DSI-NOW (1-866-437-4669)
Mon – Fri, 8:00AM – 6:00PM ET, excluding holidays

close
Close Button Icon
TURALIO Access Central is becoming
Modal Logo

During this time, you may see both program names in use.

Daiichi Sankyo remains dedicated to helping patients find financial assistance and resources to receive their medications with confidence. AccessCentral4U is here to provide support and information to help.

You are now leaving
logo
Continue
Stay on TURALIO4U
Welcome to
Modal Logo

Please select if you are a US Healthcare Professional or Patient

For US Healthcare Professional
For Patients

Helpful Resources

When sent along with the prescription, this form allows Biologics to determine coverage and assess eligibility for financial assistance programs. This form requires a patient’s or representative’s signature.
The completion and submission of coverage-related documentation are the responsibility of the patient and healthcare provider. Daiichi Sankyo, Inc. makes no representation or guarantee concerning coverage or reimbursement for any service or item. A completed Patient Enrollment Form includes signatures from both the physician and the patient. Before submitting, please ensure all required information is provided.

Support Organizations

The entities below are independent from and unaffiliated with Daiichi Sankyo, Inc. and Daiichi Sankyo, Inc. does not review or endorse any of the organizations listed below.

General Cancer Resources

National Organization for Rare Disorders

Phone: 1-203-744-0100

TGCT Support

Phone: 973-837-9092

Support Groups and Services

CancerCare®

Phone: 1-800-813-HOPE (1-800-813-4673)

Patient Access Network Foundation

Phone: 1-866-316-7263

Patient Advocate Foundation

Phone: 1-800-532-5274

Sarcoma Alliance

Phone: 1-415-381-7236

Need support?

Call Daiichi Sankyo AccessCentral4U today.

1-866-4-DSI-NOW (1-866-437-4669)
Mon – Fri, 8:00AM – 6:00PM ET, excluding holidays

Call Biologics (specialty pharmacy) with questions about TURALIO prescriptions and patient support

1-800-850-4306
Contact Icon
Important Safety Information SEE MORE

INDICATION

TURALIO® (pexidartinib) is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.

WARNING: HEPATOTOXICITY

  • TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct syndrome.
  • Monitor liver tests prior to initiation of TURALIO and at specified intervals during treatment. Withhold and dose reduce or permanently discontinue TURALIO based on severity of hepatotoxicity. Monitoring and prompt cessation of TURALIO may not eliminate the risk of serious and potentially fatal liver injury.
  • TURALIO is available only through a restricted program called the TURALIO Risk Evaluation and Mitigation Strategy (REMS) Program.

CONTRAINDICATIONS:

None

WARNINGS AND PRECAUTIONS

Hepatotoxicity

  • Hepatotoxicity, including liver failure and life-threatening vanishing bile duct syndrome (VBDS), ductopenia, and symptomatic cholestasis (including severe pruritus) can occur in patients treated with TURALIO and can occur despite monitoring and prompt drug cessation.
  • The mechanism of cholestatic hepatotoxicity is unknown and its occurrence cannot be predicted. It is unknown whether liver injury can also occur in the absence of increased transaminases.
  • Of the first 609 patients who received TURALIO under the REMS program, 32 (5.3%) developed a liver injury event of concern, defined as any serious liver-related outcome or any liver abnormality that triggers drug discontinuation per the US Prescribing Information. These 32 patients developed liver toxicity within 71 days of the first dose of TURALIO; ten required hospitalization and two developed VBDS. Sixteen of the 32 patients had not fully recovered at the time of the analysis, including 6 patients followed for at least 6 months after discontinuation.
  • Among 768 patients who received TURALIO in clinical trials, there were two irreversible cases of cholestatic liver injury. One patient with advanced cancer and ongoing liver toxicity died and one patient with a confirmed case of VBDS required a liver transplant.
  • In ENLIVEN, 3 of 61 (5%) patients who received TURALIO developed signs of serious liver injury, defined as alanine aminotransferase (ALT) or alanine aminotransferase (AST) ≥3 × upper limit of normal (ULN) with total bilirubin ≥2 × ULN. In these patients, peak ALT ranged from 6 to 9 × ULN, peak total bilirubin ranged from 2.5 to 15 × ULN, and alkaline phosphatase (ALP) was ≥2 × ULN. ALT, AST, and total bilirubin improved to <2 Å~ ULN in these three patients 1 to 7 months after discontinuing TURALIO.
  • Avoid TURALIO in patients with preexisting increased serum transaminases, total bilirubin, or direct bilirubin (>ULN); or active liver or biliary tract disease, including increased ALP.
  • Monitor liver tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of TURALIO, weekly for the first 8 weeks, every 2 weeks for the next month and every 3 months thereafter.
  • Withhold and dose reduce, or permanently discontinue TURALIO based on the severity of the hepatotoxicity. Refer patients to a hepatologist if liver tests do not return to normal. Rechallenge with a reduced dose of TURALIO may result in a recurrence of increased serum transaminases, bilirubin, ALP or other signs of liver injury. Monitor liver tests weekly for the first month after rechallenge

TURALIO REMS

  • Requirements include: 1) prescribers must be certified by enrolling and completing training, 2) patients must complete and sign an enrollment form for inclusion in a patient registry, and 3) pharmacies must be certified and must dispense only to patients who are authorized (enrolled in the REMS patient registry).
  • Further information is available at www.TURALIOREMS.com or 1-833-887-2546.

Embryo-Fetal Toxicity

  • TURALIO may cause fetal harm when administered to a pregnant woman. Advise patients of reproductive potential of the potential risk to a fetus. Verify pregnancy status in females of reproductive potential prior to the initiation of TURALIO.
  • Advise females of reproductive potential to use an effective nonhormonal method of contraception. TURALIO can render hormonal contraceptives ineffective during treatment with TURALIO and for 1 month after the final dose.
  • Advise males with female partners of reproductive potential to use effective contraception during treatment with TURALIO and for 1 week after the final dose.

Potential Risks Associated with a High-Fat Meal

  • Taking TURALIO with a high-fat meal increases pexidartinib concentrations, which may increase the incidence and severity of adverse reactions, including hepatotoxicity.
  • Instruct patients to take TURALIO with a low-fat meal (approximately 11 to 14 grams of total fat) and to avoid taking TURALIO with a high-fat meal (approximately 55 to 65 grams of total fat).

ADVERSE REACTIONS

  • The most common adverse reactions (>20%) were increased lactate dehydrogenase (92%), increased AST (88%), hair color changes (67%), fatigue (64%), increased ALT (64%), decreased neutrophils (44%), increased cholesterol (44%), increased ALP (39%), decreased lymphocytes (38%), eye edema (30%), decreased hemoglobin (30%), rash (28%), dysgeusia (26%), and decreased phosphate (25%).

DRUG INTERACTIONS

  • Hepatotoxic products: Avoid coadministration in patients with increased serum transaminases, total bilirubin, or direct bilirubin (>ULN) or active liver or biliary tract disease.
  • Moderate or strong CYP3A inhibitors and UGT inhibitors: Concomitant use may increase pexidartinib concentrations. Reduce TURALIO dosage if concomitant use cannot be avoided.
  • Strong CYP3A inducers: Avoid concomitant use due to decreased pexidartinib concentrations.
  • Acid-reducing agents: Avoid concomitant use of proton pump inhibitors due to decreased pexidartinib concentrations. Use histamine-2 receptor antagonists or antacids if needed.
  • CYP3A substrates: Avoid concomitant use where minimal concentration changes may lead to serious therapeutic failure (e.g., hormonal contraceptives) due to decreased concentrations of CYP3A substrates.

USE IN SPECIFIC POPULATIONS

  • Lactation: Advise not to breastfeed and for at least 1 week after the final dose.
  • Renal impairment: Reduce the dosage for patients with mild to severe renal impairment.
  • Hepatic impairment: Reduce the dosage for patients with moderate hepatic impairment. TURALIO has not been studied in patients with severe hepatic impairment.
To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc, at 1-877-437-7763 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Please see accompanying Full Prescribing Information, including Boxed WARNING, and Medication Guide.